Fusion Pharmaceuticals (FUSN) Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy Feb 16, 2024 08:45AM
Fusion Pharmaceuticals (FUSN) Announces Clinical Program and Manufacturing Updates Jan 4, 2024 04:06PM
Fusion Pharmaceuticals Inc. (FUSN) Reports Q1 Earnings; Provides Clinical Program Updates May 11, 2023 07:16AM
Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T Feb 13, 2023 04:06PM